Completed Study Validates AI Eye-Tracking Platform for Cognitive Dysfunction Screening — Implications for Early Detection

References

1. 1.Anderson, T. J., & MacAskill, M. R. (2013). Eye movements in patients with neurodegenerative disorders. Nature Reviews Neurology, 9(2), 74-85. https://doi.org/10.1038/nrneurol.2013.74
2. 2.Australian Institute of Health and Welfare. (2023). Dementia in Australia. AIHW. https://www.aihw.gov.au/reports/dementia/dementia-in-australia
3. 3.Crawford, T. J., Higham, S., Renvoize, T., Patel, J., Dale, M., Suriya, A., & Tetley, S. (2005). Inhibitory control of saccadic eye movements and cognitive impairment in Alzheimer's disease. Biological Psychiatry, 57(9), 1052-1060. https://doi.org/10.1016/j.biopsych.2004.10.013
4. 4.Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., ... & Cummings, J. L. (2014). Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet Neurology, 13(6), 614-629. https://doi.org/10.1016/S1474-4422(14)70090-0
5. 5.Garbutt, S., Matlin, A., Hellmuth, J., Schenk, A. K., Johnson, J. K., Rosen, H., ... & Boxer, A. L. (2008). Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain, 131(5), 1268-1281. https://doi.org/10.1093/brain/awn047
6. 6.Kahana Levy, N., Lavidor, M., & Vakil, E. (2018). Prosaccade and antisaccade paradigms in persons with Alzheimer's disease: A meta-analytic review. Neuropsychology Review, 28(1), 16-31. https://doi.org/10.1007/s11065-017-9362-4
7. 7.Molitor, R. J., Ko, P. C., & Ally, B. A. (2015). Eye movements in Alzheimer's disease. Journal of Alzheimer's Disease, 44(1), 1-12. https://doi.org/10.3233/JAD-142973
8. 8.Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. (2015). World Alzheimer Report 2015: the global impact of dementia. Alzheimer's Disease International. https://www.alzint.org/u/WorldAlzheimerReport2015.pdf
9. 9.Sun Yat-sen University. (2024). The Development of an Artificial Intelligence Platform for Screening and Referral of Cognitive Dysfunction. ClinicalTrials.gov. NCT04236375. https://clinicaltrials.gov/study/NCT04236375